[Show abstract][Hide abstract] ABSTRACT: Carboplatin-containing regimens are sometimes preferred for patients with advanced non-small cell lung cancer.
Eighty-three patients with stage III-IV non-small cell lung cancer received 3 to 4 cycles of carboplatin AUC 5 on day 2 and gemcitabine 1250 mg/m2 on days 1 and 8 every 21 days.
The overall response rate was 43.4%. Results obtained from elderly and non-elderly groups were compared using the logrank method. Median overall survival and progression-free survival were 11 and 7 months, respectively (12 and 7 months, non-elderly group; 6.5 and 5 months, elderly group, P = 0.28 and 0.25 respectively). Grade 3-4 toxicity included neutropenia, thrombocytopenia, anemia, nausea/vomiting, and diarrhea. Incidences of grade 3-4 toxicity were similar for elderly and non-elderly patients.
Data confirm that carboplatin-gemcitabine is an active and well-tolerated regimen in advanced non-small cell lung cancer and could be investigated in elderly patients.
[Show abstract][Hide abstract] ABSTRACT: The "International Prognostic Index" (IPI) has been published for patients with histological intermediate grade malignancy non-Hodgkin's lymphoma (NHL) according to the Working Formulation (WF). The IPI is based on pre-treatment clinical characteristics: age, performance status, Ann Arbor stage, extranodal sites, serum lactate-dehydrogenase concentration. We investigated whether the IPI also had prognostic value for NHL patients with a low grade malignancy or high grade malignancy according to the WF.
Our series included 192 patients with NHL, diagnosed in a single institution between 1986 and 1998. In each patient the relationship among IPI, response to therapy and survival was investigated.
The IPI turned out to be of prognostic value for response rate and survival in our unselected cohort of patients, as well. In each of the three WF classes separately (low, intermediate, high grade malignancy), the four IPI classes showed going from low to high risk substantially decreasing response rates and survival percentages.
The IPI is confirmed as an important tool for prognostic evaluation of NHL patients: an integration of IPI, histological grading and serum beta 2-microglobulin concentration is supported.
Recenti progressi in medicina 12/2003; 94(11):494-500.
[Show abstract][Hide abstract] ABSTRACT: A series of 24 consecutive patients affected by myelofibrosis with myeloid metaplasia was reviewed. The clinical-pathological features at onset were similar to those reported in literature; in particular in all the patients we observed splenomegaly and the typical leuko-erythroblastic picture in peripheral blood. The median survival of our series was of 57 months; the deaths were caused by severe anaemia and/or infection and/or haemorrhage; the blastic terminal transformations were rare. According to other authors, unfavourable prognostic factors in our patients were: male sex, advanced age, hepatomegaly, the presence of systemic signs, anaemia, leukocytosis, leukopenia, high number of circulating erythroblasts, thrombocytopenia, osteomyelosclerosis. We have confirmed the clinical value of three staging prognostic systems: the system proposed by Njoku based on haemoglobin level and reticulocytes number, the system proposed by Visani based on haemoglobin and circulating myeloid precursors number, the system proposed by Dupriez based on haemoglobin and white blood cells number.